Brainstorm Cell Therapeutics, Inc.
BCLI
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.49M
Close$
$-0.02
102.1% downside
Current Fair Value
102.1% downsideOvervalued by 102.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.49 Million |
|---|---|
| Enterprise Value | $10.96 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.11 |
| Beta | 0.28 |
| Outstanding Shares | 11,034,775 |
Return
| Return on Equity | -136.67% |
|---|---|
| Return on Assets | 2679.16% |
| Return on Invested Capital | -27.60% |
Valuation & Multiples
| P/E Ratio | -0.91 |
|---|---|
| PEG | 0.52 |
| Price to Sales | - |
| Price to Book Ratio | -0.47 |
| Enterprise Value to Revenue | 12.44 |
| Enterprise Value to EBIT | 3.55 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 17, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 3.69% |
|---|---|
| Total Invested | $1,727▼ 99.35% |
| Investors Holding | 5▼ 28.00% |
ESG Score
No data
About Brainstorm Cell Therapeutics, Inc.
CEO: Chaim Lebovits